Genelux Corporation (GNLX)
2.56
-0.04 (-1.54%)
At close: Apr 02, 2025, 3:59 PM
2.54
-0.78%
After-hours: Apr 02, 2025, 04:05 PM EDT
-1.54% (1D)
| Bid | 2.5 |
| Market Cap | 96.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.95 |
| PE Ratio (ttm) | -2.69 |
| Forward PE | -3.31 |
| Analyst | Buy |
| Ask | 2.78 |
| Volume | 161,947 |
| Avg. Volume (20D) | 236,903 |
| Open | 2.56 |
| Previous Close | 2.60 |
| Day's Range | 2.52 - 2.70 |
| 52-Week Range | 1.60 - 5.88 |
| Beta | -1.46 |
About GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment o...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 26, 2023
Employees 25
Stock Exchange NASDAQ
Ticker Symbol GNLX
Website https://www.genelux.com
Analyst Forecast
According to 4 analyst ratings, the average rating for GNLX stock is "Buy." The 12-month stock price forecast is $17.5, which is an increase of 583.59% from the latest price.
Stock Forecasts1 week ago
-12.6%
Genelux shares are trading lower after the company...
Unlock content with
Pro Subscription
4 months ago
-19.73%
Genelux shares are trading lower. HC Wainwright & Co. cut its price target on the stock from $32 to $30.
